Details

Autor(en) / Beteiligte

• Lee, Marlene
• Schnura, Eva
• Sehouli, Jalid
• Klews, Julia
• Harter, Philipp
• Chekerov, Radoslav
• Inci, Melisa Gülhan
• Zimmermann, Manuela
• Nigemann, Phil
• Roll, Stephanie
• Reinhold, Thomas
• Willich, Stephan N
• Liebl, Max Emanuel
• Pirmorady-Sehouli, Adak
• Algharably, Engi
• Flethe, Chiara
• Lindemann, Helena
• Heitz, Florian
• Moubarak, Malak
• Rosenbaum, Stephanie

Titel

1052 KORE INNOVATION: the first prospective clinical trial to assess a perioperative procedure to reduce postoperative complications in ovarian cancer patients – first experiences about adherence to preoperative carbohydrate loading

Ist Teil von

• International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A394-A395

Ort / Verlag

Oxford: BMJ Publishing Group Ltd

Erscheinungsjahr

2024

Link zum Volltext

Beschreibungen/Notizen

• Introduction/BackgroundThe implementation of perioperative care pathways such as the Enhanced Recovery After Surgery (ERAS) program can improve the quality of healthcare in complex operations such as the multivisceral surgery for patients with ovarian cancer. Adherence to individual ERAS-items is essential for effective treatment. One ERAS-item is the preoperative carbohydrate intake (CHO), which is associated with the reduction of postoperative insulin resistance and improved clinical outcomes.MethodologyThe KORE INNOVATION is an ongoing clinical trial to assess the effects of an innovative multimodal perioperative care pathway consisting of prehabilitation combined with an ERAS-pathway to reduce complications for patients undergoing surgery for ovarian cancer. Preoperative carbohydrate loading (CHO) is given to the patients using a complex carbohydrate drink (CCD). Patients receive two bottles of CDD the evening before and one bottle of CDD two hours prior to surgery and are instructed by a specialized KORE nurse to self-administer the bottles.Results378 patients were included in the preliminary, descriptive analyses. 191 patients (50.5%) consumed the full dose of CHO (3 bottles CDD), while 258 (68.3%) patients consumed at least one bottle. 67.7% of patients consumed CHO in the evening before the operation and 58.5% in the morning of the operation. Pre-existing diabetes was a contraindication and was present in 5.8%. Reasons for not consuming CHO were: not received from staff (4.8%), refusal by patient (0.5% in the evening, 1.6% in the morning), poor taste of CDD (1.9% in the evening, 4% in the morning).ConclusionThe main reason for non-adherence to the CHO rejection of the CDD due to the poor taste according to the patients. Through patient empowerment by education and self-monitored ingestion, logistical factors (e.g. CDD not received) could be avoided and adherence could be increased.DisclosuresKORE INNOVATION is funded by the Innovationsfinds des Gemeinsamen Bundesausschuss (GBA), 01NVF18021.